Zagotenemab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease (AD)
Conditions
Alzheimer Disease (AD)
Trial Timeline
Apr 30, 2018 → Oct 25, 2021
NCT ID
NCT03518073About Zagotenemab + Placebo
Zagotenemab + Placebo is a phase 2 stage product being developed by Eli Lilly for Alzheimer Disease (AD). The current trial status is completed. This product is registered under clinical trial identifier NCT03518073. Target conditions include Alzheimer Disease (AD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03518073 | Phase 2 | Completed |
Competing Products
20 competing products in Alzheimer Disease (AD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 + Placebo | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| donanemab | Eli Lilly | Phase 2 | 52 |
| ATH-1017 | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 25 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 25 |
| Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet | Cassava Sciences | Phase 2 | 44 |